US-based DiscoveRx’s BioSeek division launched BioMAP panel, a primary human cell-based assay platform, for oncology research.
The BioMAP panel comprising primary human cell-based tumor-host model systems allows the researchers to easily assess the phenotypic impact of candidate compounds on tumor microenvironment biology.
The panel facilitates better predicting of in vivo drug activities and forecasting potential clinical outcomes with respect to drug efficacy and safety.
BioSeek scientific director and general manager Dr Ellen Berg noted these oncology-focused BioMAP systems will support predictive and physiologically relevant cancer compound development from early discovery through pre-clinical development stages.
"They capture human tumor-host activities that can be modulated by a number of clinically relevant mono-therapies as well as drug combinations involving small molecule chemotherapeutics and biologics," Dr Berg added.
"Such BioMAP models recapitulate complex interactions between tumor cells, stromal and/or vascular tissue and recruited, infiltrating immune cells to the tumor."
BioMAP can support the testing of pre-clinical strategies involving both development compounds and approved oncology drugs.